Who Exports Paclitaxel from India — 319 Suppliers Behind a $83.1M Market
India's paclitaxel export market is supplied by 319 active exporters who collectively shipped $83.1M across 4,928 shipments. FRESENIUS KABI ONCOLOGY LIMITED leads with a 30.2% market share, followed by MSN LABORATORIES PRIVATE LIMITED and INTAS PHARMACEUTICALS LIMITED. The top 5 suppliers together control 60.7% of total export value, reflecting a concentrated market structure.
Top Paclitaxel Exporters from India — Ranked by Export Value
FRESENIUS KABI ONCOLOGY LIMITED is the leading paclitaxel exporter from India, holding a 30.2% share of the $83.1M market across 4,928 shipments from 319 exporters. The top 5 suppliers — FRESENIUS KABI ONCOLOGY LIMITED, MSN LABORATORIES PRIVATE LIMITED, INTAS PHARMACEUTICALS LIMITED, JODAS EXPOIM PRIVATE LIMITED, PANACEA BIOTEC PHARMA LIMITED — collectively control 60.7% of total export value, indicating a moderately concentrated market. Individual shares are: FRESENIUS KABI ONCOLOGY LIMITED (30.2%), MSN LABORATORIES PRIVATE LIMITED (9.3%), INTAS PHARMACEUTICALS LIMITED (7.1%), JODAS EXPOIM PRIVATE LIMITED (7.1%), PANACEA BIOTEC PHARMA LIMITED (6.9%).
Top Paclitaxel Exporters from India
Ranked by export value · 319 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | FRESENIUS KABI ONCOLOGY LIMITED PACLITAXEL CONCENTRATE FOR PREPARATION OPACLITAXEL KABI INJ.300MG/50ML VIAL B.NOPHARMA DRUGS & MEDI PACLITAXEL INJ USP 6 | $25.1M | 24 | 30.2% |
| 2 | MSN LABORATORIES PRIVATE LIMITED PACLITAXEL INJ 300MG/50MLPACLITAXEL INJ 300MG/50ML 1'SPACLITAXEL INJ USP 300MG 50ML AP US | $7.7M | 2 | 9.3% |
| 3 | INTAS PHARMACEUTICALS LIMITED PHARMA DRUGS & MEDI PACLITAXEL INJ USP 6PACLITAXEL INJ 300MG/50MLPACLITAXEL INJ 300MG/50ML 1'S | $5.9M | 19 | 7.1% |
| 4 | JODAS EXPOIM PRIVATE LIMITED PACLITAXEL CONCENTRATE FOR PREPARATION OPACLITAXEL ELFA 300MG/50ML(CONCENTRATE F | $5.9M | 2 | 7.1% |
| 5 | PANACEA BIOTEC PHARMA LIMITED PACLITAXEL CONCENTRATE FOR PREPARATION OPACLITAXEL B/N.907024024 M/D.01/2025 E/D.12/2026.PACLITAXEL ELFA 300MG/50ML(CONCENTRATE F | $5.7M | 15 | 6.9% |
| 6 | VENUS REMEDIES LIMITED INTAXEL PACLITAXEL USP INJ 300MG 50MLVIALINTAXEL USP INJ. 300MG/50MLACUPAXIL 30 MG PRIVATEPACLITAXEL INJECTION 30 MG | $3.2M | 18 | 3.8% |
| 7 | ACCURE LABS PRIVATE LIMITED ACUPAXIL 30 MG PRIVATEPACLITAXEL INJECTION 30 MGPACLITAXEL INJECTION USP 30MG/5MLACUPAXIL 30 MG PRIVATE PACLITAXEL INJECTION | $2.5M | 1 | 3.0% |
| 8 | ALEMBIC PHARMACEUTICALS LIMITED PACLITAXEL INJ 300MG/50MLPACLITAXEL INJ 300MG/50ML 1'SPACLITAXEL INJ USP 300MG 50ML AP US | $2.5M | 1 | 3.0% |
| 9 | KARDI TRADING PRIVATE LIMITED PHARMA DRUGS & MEDI PACLITAXEL INJ USP 6INTAXEL PACLITAXEL USP INJ 300MG 50MLVIALINTAXEL USP INJ. 300MG/50ML | $2.4M | 7 | 2.9% |
| 10 | EUGIA PHARMA SPECIALITIES LIMITED PACLITAXEL INJECTION 300 MG / 50 ML -PACLITAXEL INJECTION 300MG/50ML -FRANCE)PACLITAXEL INJECTION 300 MG / 50 ML (6 M | $2.1M | 1 | 2.5% |
| 11 | CIPLA LIMITED PACLITAXEL INJ 300MG/50MLPACLITAXEL INJ 300MG/50ML 1'SPACLITAXEL INJ USP 300MG 50ML AP US | $1.7M | 5 | 2.1% |
| 12 | GETWELL PHARMA INDIA PRIVATE LIMITED CELTAX PACLITAXEL INJECTION 150MGPACLINANO 100MG FOR INJ. SUSPENSION) | $1.7M | 11 | 2.0% |
| 13 | SP ACCURE LABS PRIVATE LIMITED INTAXEL PACLITAXEL USP INJ 300MG 50MLVIALINTAXEL USP INJ. 300MG/50MLACUPAXIL 30 MG PRIVATEPACLITAXEL INJECTION 30 MG | $1.3M | 9 | 1.5% |
| 14 | NV REMEDIES PRIVATE LIMITED | $1.2M | 3 | 1.5% |
| 15 | NAPROD LIFE SCIENCES PRIVATE LIMITED INTAXEL PACLITAXEL USP INJ 300MG 50MLVIALINTAXEL USP INJ. 300MG/50MLPALIT SPAL 100MG (PACLITAXEL PROTEIN | $1.1M | 14 | 1.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Paclitaxel exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Intas Pharmaceuticals Limited | Warning Letter, December | Yes, April 2007 | Yes | Not verified | Received FDA warning letter in December 2022 for data falsification at Sanand fa |
| Alembic Pharmaceuticals Limited | Approved | Yes | Yes | Not verified | WHO-GMP certified; EU-GMP compliant as of July 2025. |
| Cipla Limited | Approved | Yes | Yes | Not verified | WHO-GMP certified; EU-GMP compliant as of February 2024. |
| Panacea Biotec Pharma Limited | Not Listed | Unknown | No | Not verified | Received EU GMP non-compliance report in February 2026 for Baddi facility. |
| Venus Remedies Limited | Approved | Yes | Yes | Not verified | WHO-GMP certified; EU-GMP compliant. |
| MSN Laboratories Private Limited | Approved | Yes | Yes | Not verified | WHO-GMP certified; EU-GMP compliant. |
| Fresenius Kabi Oncology Limited | Approved | Yes | Yes | Not verified | WHO-GMP certified; EU-GMP compliant. |
| Jodas Expoim Private Limited | Approved | Yes | Yes | Not verified | WHO-GMP certified; EU-GMP compliant. |
TransData Nexus reviewed the regulatory standing of 8 leading Paclitaxel exporters from India. 6 hold US FDA facility approvals, 7 maintain WHO-GMP certification, and 7 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Paclitaxel sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Pharma Capital of India," is a pivotal center for bulk drug manufacturing. The city contributes approximately 40% of the country's bulk drug production, earning it the moniker "Bulk Drug Capital of India." This prominence is bolstered by the presence of Genome Valley, a premier biotech cluster housing over 200 life sciences companies, including global giants like Novartis, Bayer, and Sanofi. Hyderabad's robust infrastructure and skilled workforce make it a significant player in the production of active pharmaceutical ingredients (APIs) such as Paclitaxel.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its expertise in pharmaceutical formulations. Gujarat accounts for 33% of India's drug manufacturing and 28% of drug exports, with Ahmedabad and Vadodara serving as major pharmaceutical hubs. Vadodara, in particular, is home to Alembic Pharmaceuticals, a leading manufacturer of both APIs and formulations. The region's focus on formulations complements the bulk drug production capabilities of other clusters, contributing to the comprehensive supply chain for drugs like Paclitaxel.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical products. Mumbai's strategic coastal location and well-developed port facilities facilitate the efficient export of pharmaceuticals to global markets. The region hosts numerous pharmaceutical companies that leverage this logistical advantage to distribute products like Paclitaxel worldwide.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives offered by the government. This region attracts numerous pharmaceutical companies seeking cost-effective production solutions, thereby enhancing the overall capacity for drugs such as Paclitaxel.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Leverage Regional Specializations: Source bulk drugs from Hyderabad and formulations from the Ahmedabad-Vadodara corridor to capitalize on regional expertise.
- Optimize Logistics: Utilize the Mumbai-Thane-Raigad region's export infrastructure for efficient global distribution of Paclitaxel.
- Evaluate Cost Benefits: Consider the Baddi-Nalagarh region for cost-effective manufacturing options, taking advantage of available tax incentives.
By strategically engaging with these pharmaceutical clusters, companies can enhance their supply chain resilience and optimize the sourcing and distribution of Paclitaxel.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Paclitaxel exporters from India
Intas Pharmaceuticals Limited — Intas partners with mAbxience for Etanercept biosimilar
Intas Pharmaceuticals Limited announced a licensing agreement with mAbxience for the Etanercept biosimilar, aiming to expand their biosimilar portfolio and enhance global market reach. - IMPACT: This collaboration may divert resources towards biosimilars, potentially affecting Paclitaxel production and export volumes.
Impact: This collaboration may divert resources towards biosimilars, potentially affecting Paclitaxel production and export volumes.
Fresenius Kabi Oncology Limited — Fresenius Kabi acquires majority stake in mAbxience
Fresenius Kabi acquired a majority stake in mAbxience, enhancing its biologic production capabilities and strengthening its biosimilars pipeline to deliver cost-effective therapies. - IMPACT: The acquisition may lead to a strategic shift towards biosimilars, potentially impacting Paclitaxel export focus.
Impact: The acquisition may lead to a strategic shift towards biosimilars, potentially impacting Paclitaxel export focus.
Fresenius Kabi Oncology Limited — Fresenius Kabi's Ustekinumab biosimilar approved in EU and US
Fresenius Kabi received approval for its Ustekinumab biosimilar in both the European Union and the United States, marking a significant milestone in their biosimilar portfolio. - IMPACT: The approval may lead to increased focus on biosimilars, potentially affecting Paclitaxel export priorities.
Impact: The approval may lead to increased focus on biosimilars, potentially affecting Paclitaxel export priorities.
Common Questions — Paclitaxel Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which paclitaxel supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, FRESENIUS KABI ONCOLOGY LIMITED leads with 854 recorded shipments worth $25.1M. MSN LABORATORIES PRIVATE LIMITED (138 shipments) and INTAS PHARMACEUTICALS LIMITED (405 shipments) are also established high-volume exporters.
Q How many paclitaxel manufacturers are there in India?
India has 319 active paclitaxel exporters with a combined export market of $83.1M across 4,928 shipments to 142 countries. The top 5 suppliers hold 60.7% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for paclitaxel from India?
Average FOB unit price: $16.32 per unit, ranging from $0.01 to $2799.75. Average shipment value: $16.9K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 319 verified Indian exporters of Paclitaxel ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 4,928 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 142 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
4,928 Verified Shipments
319 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists